本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Aligning to the United Nations SDGs, Taiwan Institute For Sustainable Energy (TAISE) has been organizing the Global Corporate Sustainability Award (GCSA) for seven years, aiming to recognize enterprises and organizations that have made outstanding contributions to achieving sustainable development goals. The GCSA not only aims to raise awareness of sustainability principles and practices but also endeavors to acknowledge the efforts of all sectors towards sustainable development. Through the ongoing development of corporate sustainability, the GCSA aims to reach world standards, delve into multifaceted sustainability issues, and cultivate global corporate attention to corporate social responsibility and sustainability issues. The GCSA invites professional international judges to thoroughly examine participants' effectiveness in sustainability practices from diverse perspectives, serving as the best diagnostic tool for corporate sustainability check-ups. By exploring multifaceted sustainability issues, it builds bridges between Taiwan and the international community, collectively showcasing a commitment to social responsibility and sustainability. Registration for this award is open until August 10th, and we warmly welcome active participation from corporations, universities, healthcare institutions, government bodies, and NGOs. This global honorific benchmark consists of two major awards: the Sustainability Reporting Award and the Best Practice Award. The Sustainability Reporting Award aims to recognize companies that disclose transparent and credible sustainability information. Evaluation criteria include, but are not limited to, the performance outcomes of the submitted reports and their alignment with international standards such as the Global Reporting Initiative (GRI), Integrated Reporting (IR), or the Sustainability Accounting Standards Board (SASB). The Best Practice Award aims to recognize outstanding achievements in sustainability. Entrants can submit multiple case studies without restrictions on duration, project progress, or focused issues, although highlighting case outcomes is recommended. The GCSA award ceremony is held in conjunction with the largest global sustainability forum in Asia, aiming to witness the radiant manifestation of corporate social responsibility together at this grand event of sustainable development. For complete information, please visit the GCSA official website: https://globalcsaward.com/
BEIJING, Jan. 19, 2024 /PRNewswire/ -- RLX Technology (NYSE: RLX) today proudly presents its Corporate Social Responsibility Report. The report outlines the firm's annual progress in fulfilling various corporate social responsibilities, including rural revitalization, product-related responsibility, corporate governance, environmental responsibility, and employee responsibility. RLX Technology Unveils 2022-2023 Corporate Social Responsibility Report According to the report, as of 2023, RLX has invested a total of 44.3 million yuan in areas such as biodiversity conservation and rural revitalization. By the end of April 2023, RLX had effectively generated approximately 120,000 employment opportunities along the supply chain, and accumulated research and development investments totaling 800 million yuan. Navigating the delicate balance between compliance and innovation is the most crucial challenge for RLX. In pursuit of a first-class user experience, the company not only strictly adheres to regulatory requirements by developing products in line with national standards to ensure quality and safety, but is also comprehensively upgrading its research and development system. This involves establishing eight major laboratory matrices and rigorous factory quality control to enhance product innovation. The report reveals that as of April 2023, RLX has applied for nearly 900 patents globally. From child-proof locks to anti-dry burn functions, each of the eight laboratories plays a specific role in developing products that meet both regulatory requirements and user-experience expectations. The Innovation Lab, for example, focuses on material purification and flavor perception, significantly reducing the risk of alterations to product taste and flavor. The Quality and Safety Lab conducts tests such as drop and negative pressure tests to ensure product stability in extreme environments. This lab has received accreditation from China National Accreditation Service for Conformity Assessment (CNAS). Since outlining its "1+4" scientific research path in 2020, RLX has initiated nearly 50 research projects to fill the gaps in the field of vape science. The report highlights several breakthrough achievements from the past year. In November 2022, the first domestic clinical study on electronic cigarettes initiated by RLX was published in the medical SCI journal "Nicotine & Tobacco Research." By the end of April 2023, RLX had conducted 17 collaborative research projects, publishing 11 research papers in authoritative journals. In September 2023, the Feiyue All-Weather Bridge and Feiyue Convenience Bridge, constructed jointly by RLX and the China Siyuan Foundation, were inaugurated in Jizidu Village, Baiyangping Town, Enshi, Hubei Province. The Feiyue All-Weather Bridge, with a length of 58 meters and a width of 10.5 meters, features distinctive local ethnic characteristics, becoming a "new landmark" attracting tourists near the Jizidu area. The Feiyue Convenience Bridge, measuring 61 meters in length and 2.2 meters in width, has reduced the time it takes villagers to cross the river from 40 minutes to just a few minutes, alleviating transportation challenges. Both bridges have effectively stimulated the development of the local tourism industry. "From 2022 to 2023, whether in the Chinese e-cigarette industry or at RLX Technology, it has been an extremely important period. We wholeheartedly respond to policies, and actively address various changes, not only fulfilling strict compliance and providing reassuring products as 'required actions,' but also contributing our modest efforts in 'voluntary actions' such as wildlife protection and rural revitalization to enhance social well-being," said Kate Wang, Founder and CEO of RLX. https://relx-website-new.oss-cn-zhangjiakou.aliyuncs.com/yueke/Rlx%20Tech%20Corporate%20Social%20Responsibility%20Report%202022-2023.pdf
FP Markets, a global multi-asset broker announces sponsorship deal with ICC associate member Cricket Brasil to support its Youth Development Programme. SYDNEY, Dec. 12, 2023 /PRNewswire/ -- FP Markets, an Australian forex and CFDs broker, has announced a partnership with Cricket Brasil to support its thriving youth development programme which provides a pathway for children to finish schooling, attend university and build a future around the game. In its initial phase, the sponsorship will focus on supporting 3 specific areas: FP Markets enhances its Corporate Social Responsibility (CSR) programme with Sponsorship of the Cricket Brasil Youth Development Programme Education - Helping fund the university education of project leaders (known as the "Black T-shirts") through the Cricket Brasil University Scheme providing young Brazilians access to higher education and providing life-changing opportunities as well as teaching them the key core values of Respect, Leadership and Community. Infrastructure Upgrades - Completion of the Cricket Brasil indoor school and high performance center in Poços de Caldas, Minas Gerais. Community Support - Supporting the development of local development officers to help grow the game in the local communities. Craig Allison, CEO, FP Markets commented "FP Markets recognises that being an industry leader requires more than just being exceptional in the trading industry. It involves actively engaging with communities and contributing in ways that can make a real difference to people's lives. By Supporting Cricket Brasil we know we are making a real difference to the lives of young Brazilians and leaving a long-lasting positive impact on the local community through the glorious game and values set by cricket" Matt Featherstone, President Cricket Brasil "Partnerships like this make all the difference. The expansion of Cricket Brasil as a direct result of this partnership will provide more opportunities for young Brazilians to play the great game as well as join our University Scheme which educates more Cricket Development officers who in turn increase local engagement and participation." Sergio Azevedo, Mayor of Poços de Caldas: "We are very privileged in Poços de Caldas to be known as the home of Cricket Brasil. It is a very unique situation in a country synonymous with football that we have more children in the town playing Cricket than Football!" Fara Gorsi, ICC Development Manager, Americas: "The new partnership formed between FP Markets, (an Australian organization) and Cricket Brasil is a testament to their unequivocal commitment to the game and positively impacting the lives of thousands of young kids. The partnership with FP Markets will aid in the growth and development of the cricket ecosystem. As the natural trailblazers in the region, Cricket Brasil continue to strive for progress and we are very excited and proud to see Cricket Brasil grow from strength to strength in ICC Americas" FP Markets sponsorship and donation initiatives aim to empower individuals and organizations striving to improve lives through community engagement, education and innovation, diversity and inclusion, ethical business practices and sustainability and hopes these collaborations can impart lasting effects. FP Markets is committed to making a positive impact on society and the environment through its Corporate Social Responsibility initiatives. The dedication to CSR is rooted in our values, and we strive to make a difference to current and future generations by supporting projects that actually deliver. Established in 2005, FP Markets is a Multi-Regulated brand providing clients with over 10,000 tradable instruments across key asset classes and offers aggregate pricing across several top-tier liquidity providers. Additionally, FP Markets deliver Consistently Tight Spreads, Lightning Execution, Unmatched 24/7 Multilingual Customer Support, and various Account Types to suit all trading strategies and styles. Notes to Editors About FP Markets: FP Markets is a Multi-Regulated Forex and CFDs Broker with over 18 years of industry experience. The company offers highly competitive interbank Forex spreads starting from 0.0 pips. Traders can choose from the leading powerful online trading platforms, including FP Markets' Mobile App, MetaTrader 4, MetaTrader 5, WebTrader, cTrader, and Iress. The company's outstanding 24/7 multilingual customer service has been recognised by Investment Trends and awarded 'The Highest Overall Client Satisfaction Award' over five consecutive years. FP Markets has been awarded the 'Best Global Forex Value Broker' for five consecutive years (2019, 2020, 2021, 2022, 2023) at the Global Forex Awards. FP Markets has been awarded the 'Best Forex Broker – Europe' and the 'Best Forex Partners Programme – Asia' at the Global Forex Awards 2022 and 2023. FP Markets has been awarded 'Best Trade Execution' at the Ultimate Fintech Awards 2022. FP Markets was crowned 'Best CFD Broker in Africa' at FAME Awards 2023. FP Markets Awarded 'Best Trade Execution' and 'Most Transparent Broker' at the Ultimate Fintech Awards APAC 2023 For more information on FP Markets' comprehensive range of products and services, visit https://www.fpmarkets.com/. About Cricket Brasil: Total Players: 24,565 (2009 - 250) Male 12,491 Female 12,074 Cricket Centre numbers: 3 Cricket centers in place currently (Caldense, Cricket Brasil High Performance Center and Cricket Brasil Indoor Center) Regional Hubs in 4 other states: Development: 1. Poços de Caldas Hub, 2. Botelhos Hub. SP: 3. Aguaí Hub. BA: 4 Santa Luz Hub. DF: Brasília Hub Contracted Players: 14 contracted players on the Women's National Team. Another 18 players on the Women's Development Squad and 20 at the Men's Development Squad. Elite Squad age groups: 94% of players from age 16-24 Coaches (HP & Other) & Qualified Umpires/Scorers. Information submitted to ICC in 2023: Active Coaches: 139 Male 85, Female 54 Active Umpires: 143 Male 94, Female 49 Cricket Brasil is an ICC associate nation. Matt Featherstone - ICC global representative for the associate nations for 4 years and currently on the ICC Governance Committee For more information on Cricket Brasil, visit https://cricketbrasil.org/en/ Facebook: https://www.facebook.com/brasilcricket Instagram: cricketbrasil Twitter: @brasil_cricket FP Markets enhances its Corporate Social Responsibility (CSR) programme with Sponsorship of the Cricket Brasil Youth Development Programme
INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report. The annual report outlines the company's progress toward its sustainability goals and the strategies to fulfill its social responsibilities and create long-term value for stakeholders. "Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the wider community," said John Rim, President and CEO of Samsung Biologics. "We will continue to leverage our expertise and experience to accelerate the delivery of net-zero healthcare and engage with our suppliers and partners to amplify our collective efforts." Key highlights of the report include: Establishing a net-zero pathway: As part of the company's mission to deliver net zero by 2050 or earlier, Samsung Biologics established new milestones: to cut 32% of direct emissions by 2030 and 62% by 2040 while reducing 36% of suppliers' emissions by 2030 and 73% by 2040. Last year, the company also committed to 100% renewable power through the RE100 initiative. Prioritizing sustainable leadership: In recognition of the company's commitment to the creation of sustainable markets, Samsung Biologics was the first leading biopharma CDMO to receive the Sustainable Markets Initiative's (SMI) Terra Carta Seal, which is awarded to companies whose ambitions align with those of the Terra Carta, a recovery plan for Nature, People, and Planet. Samsung Biologics is also engaging its suppliers as part of a broader Supply Chains Working Group initiative within the SMI's Health Systems Task Force to identify carbon reduction options to achieve net zero in its supply chain. Implementing responsible business practices: Samsung Biologics joined the United Nations Global Compact, a major global corporate sustainability initiative, to demonstrate its continued commitment to sustainable business practices, as well as to implement the initiative's 10 principles addressing human rights, labor standards, the environment and anti-corruption. Strengthening risk management practices and transparent corporate governance: To address risks at all levels, Samsung Biologics implemented an enterprise-wide risk management system to strengthen the company's sustainable operations. The company established an ESG committee to oversee the overall governance, reporting, and policies of ESG-related tasks. For transparent governance, Samsung Biologics obtained ISO37001 (Anti-Bribery Management Systems), a framework for implementing reasonable and proportionate measures to prevent bribery and corruption. Accelerating action across the supply chain: As a sustainable CDMO partner, Samsung Biologics conducted ESG assessments with its suppliers to minimize potential risks, build a stable network, and establish green strategies to achieve carbon neutrality across supply chains. Nurturing global talents: The company committed to building a strong bio community by fostering local and global experts to drive innovation and encourage growth while giving back to local organizations through volunteer programs. Samsung Biologics also hosted representatives from the World Health Organization's human resource training hub to offer biologics development and manufacturing courses. "Samsung Biologics is engaged in this work because we want to leave the world better than we found it," Rim added. "2022 was a foundational year for us, and we are steadfast in our commitment to drive substantial progress and make a more meaningful impact in 2023 and beyond." The full report is available here. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish, as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scale to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demands, Samsung Biologics fully completed Plant 4, which will further advance the company's standing as the world's largest manufacturing facility at a single site—holding a 604KL total capacity—and announced plans to construct Plant 5, which will be operational in April of 2025. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Contact Claire KimHead of Marketing Communicationcair.kim@samsung.com
BEIJING, April 28, 2023 /PRNewswire/ -- SANY Heavy Industry ("SANY", SSE: 600031), a leading global heavy machinery manufacturer, has published the annual Corporate Social Responsibility (CSR) Report, detailing the group's progress and achievements of social responsibility strategy and practice with heightened emphasis on sharing SANY's experience in tackling the climate challenges. Upholding the mission of "Quality Changes the World," SANY remains true to its aspirations and thrives to build a better world with its customers and partners. Adhering to the strategy of "intelligent digitalization, electrification, and internationalization," SANY has been consistently improving the corporate governance and risk management efficiency, driving sustainable development through technological innovations, and meeting environmental governance targets to pursue green economy. SANY is also promoting the United Nations Sustainable Development Goals and reaching China's carbon peaking and carbon neutralization goals, while taking better care of employees, focusing on talent development, and actively investing in and engaging in social welfare events. "SANY has always been actively fulfilling our economic, social, and environmental responsibilities to achieve sustainable development. Looking ahead into 2023, we will continue to seize opportunities and collaborate with our partners and all stakeholders to explore a sustainable development path that tackles global challenges, creates greater value for employees, shareholders, and society, and contributes to reaching the global sustainable development goals," said Xiang Wenbo, chairman of SANY Heavy Industry. Intelligent digitalization, electrification, and internationalization: SANY's global roadmap for the transformative time SANY's global development roadmap emphasizes leveraging intelligent digitalization to reach the "Dual Carbon" goals, advancing electrification development to target clean energy opportunities, and accelerating global industrial layout. The group is shifting conventional manufacturing and consumption models towards green, energy-saving, and circular development. Driving the future with the power of data, its intelligent digitalization strategy is leading the industry's technological progress, especially in the area of low-carbon transformation of product development – integrating clean technology optimization for construction machinery equipment, including pure electric and hydrogen energy technologies. SANY is also stepping up its commitment to allocate more resources in expanding the overseas market and sales network. It recorded an annual international sales revenue of 36.571 billion yuan (USD 5.3 billion) in 2022. Strengthening corporate governance to promote technological innovation, sustainable and green development, people development and social responsibility SANY has established a standardized and effective risk management and internal control structure to achieve long-term sustainable development, while improving the systems of R&D, quality control, and supplier management with sustainability the key to the corporate governance processes. In 2022, SANY invested 7.826 billion yuan (USD 1.13 billion) in R&D, representing a 1.68 percent increase year-on-year and accounting for 9.78 percent of its operational revenue. SANY is implementing clean production technologies to conserve resources, boost recycling, and reduce environmental pollution. In 2022, it invested 3.22 million yuan (USD 466,673.31) in photovoltaic projects that generate an average of 900,000 KWH annually, with its total clean energy usage amounting to 16.013 million KWH. SANY also invested over 140 million yuan (USD 20.29 million) to control gas emissions and reduce VOCs emissions by 134.83 tons. Building on a human touch, SANY has been improving its safety production and occupational health management systems to guarantee and support the well-being and safety of employees and suppliers. In addition, it has organized various events for employees to promote engagement and communication, as well as creating a better environment for work and life. In 2022, SANY employees completed 687.4 hours of volunteer work. The group's total investment in various social welfare projects reached 45.769 million yuan (USD 6.63 million), encompassing poverty alleviation, disaster relief, and public welfare initiatives. For more information about SANY Group, the parent company of SANY Heavy Industry. please visit www.sanyglobal.com or follow us on Facebook or YouTube. Media contact: Yolanda, rongy@sanyglobal.comSales Hotline: +86-731-85835199
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the 2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating Expert Committee, for the outstanding performance reported. In 2022, Fosun Pharma was also awarded honors including the "Annual Enterprise of Corporate Social Responsibility Award" from the People's Daily Online, a ranking on the Fortune China ESG Impact List, and an improvement of its MSCI ESG rating to Level A. Fosun Pharma fully respects the legal rights of shareholders, employees, clients and consumers, suppliers, communities and other stakeholders, and actively cooperates with them to jointly promote its sustainable and healthy development. The report fully discloses Fosun Pharma's strategy, practices and achievements in social responsibility during 2022 to its stakeholders, providing systematic disclosure of the Company's key performance that year incorporating healthcare industry material topics, in terms of "responsible management", "responsible operations", "responsible sourcing", "responsible employment", "environmental responsibility" and "community responsibility", and presentation in terms of R&D and innovation, inclusivity of medical care, product and service quality, environmental protection, supply chain management sustainability, employee development and diversification, occupational health and safety, public welfare, etc. Fosun Pharma has always attached importance to innovation for sustainable development, accelerating the R&D, transformation and launch of its innovative technologies and products so as to provide more accessible, affordable healthcare products and services to the public. Over the years, Fosun Pharma has continuously enriched its product portfolio through both independent R&D and external cooperation, benefiting patients with numerous products including Artesun® (Artesunate for Injection), Han Li Kang® (Rituximab Injection), Han Qu You® (Trastuzumab for Injection), Su Ke Xin® (Avatrombopag Maleate Tablets), Han Da Yuan® (Adalimumab Injection), and Yescarta® (Axicabtagene Ciloleucel Injection). In addition, Fosun Pharma possesses multiple innovative drugs and new indications included in the latest version of the National Medical Insurance Drug Catalogue, such as Akynzeo® (Netupitant/Palonosetron Capsules), the only imported innovative antiemetic to achieve success in China's national drug price negotiations, and Otezla® (Apremilast Tablets), the world's first orally-targeted small-molecule drug approved for psoriasis treatment. These further improve drug accessibility and affordability, benefiting a greater number of Chinese patients. In the field of rare diseases, Fosun Pharma has invested in drugs for infantile spasms, idiopathic pulmonary fibrosis and pulmonary hypertension, promoting the R&D and accessibility of related innovative drugs. Through its strengths, Fosun Pharma is also helping to solve drug accessibility problems in developing countries and underdeveloped areas. In 2022, a Fosun Pharma subsidiary signed an agreement with the Medicines Patent Pool (MPP) to produce and supply two high-quality, affordable oral COVID-19 drugs to low- and middle-income countries in agreed regions worldwide. By the end of 2022, Fosun Pharma's self-developed antimalarial innovative drug Artesun® (Artesunate for Injection) had helped more than 56 million patients with severe malaria worldwide. Moreover, Fosun Pharma owns industry-leading capability in in&out licensing and internationalization, maximizing the value of each innovative product. Henlius, a group member, has successively licensed out a number of products, such as Organon, Eurofarma and GetzPharma, to overseas companies, achieving wide recognition for the excellent quality, safety and efficacy of its drugs and benefiting increased numbers of patients worldwide. The innovative drug Artesun® (artesunate for injection) has treated more than 56 million severe cases of malaria worldwide Furthermore, Fosun Pharma is continually striving for excellence, improving its product quality and medical services, and launched Fosun Pharma Operation Excellence (FOPEX) in 2016. Fosun Health, a group subsidiary, is also further improving diagnosis and treatment capabilities through integration of online and offline resources, providing users with high-quality, full-life-cycle medical and health management services. In terms of the environment, health and safety (EHS), the Company has continually increased its investment in environmental protection, promoting air pollution control to achieve energy conservation, emissions reduction and environmental protection. Meanwhile, it has also continuously promoted a green supply chain, contributing to improving supply chain sustainable development in the industry. In terms of public welfare, Fosun Pharma set up a special fund for the "Fosun Pharma Health Care Initiative", in conjunction with the Fosun Foundation (Shanghai), to carry out various activities related to rural revitalization, health care and educational support. For example, Fosun Pharma, together with the Fosun Foundation and Genuine Biotech, donated RMB 100 million worth of Azvudine, an oral COVID-19 drug, to rural areas in China, to ensure its accessibility there, especially for elderly people, patients with chronic underlying diseases and the immunocompromised, safeguarding the health of more people. In future, Fosun Pharma will remain committed to its active social responsibility strategy and brand philosophy of "Innovation for Good Health", helping everyone obtain high-quality pharmaceutical products and medical services as necessary, to contribute to the aim of "Better Health for Families Worldwide".
A12 藝術空間
Corporate Social Responsibility
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
